| OPZELURA INCYTE HOLDINGS CORPORATION
2186625 05 Apr 2022 | on 21 Jun 2023 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the treatment of dermatological disorders. Class 016 Class 016 Paper Goods and Printed Material Printed publications, namely, brochures, newsletters, and pamphlets relating to medical issues, procedures, disease symptoms, patient support and community building. Class 044 Medical, Beauty & Agricultural Services Providing medical information to healthcare providers and patients relating to dermatological disorders. | | | OPZELURA INCYTE HOLDINGS CORPORATION
2143507 20 Sep 2021 | on 21 Jun 2023 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for the treatment of dermatological disorders. Class 016 Class 016 Paper Goods and Printed Material Printed publications, namely, brochures, newsletters, and pamphlets relating to medical issues, procedures, disease symptoms, patient support and community building. Class 044 Medical, Beauty & Agricultural Services Providing medical information to healthcare providers and patients relating to dermatological disorders. | | | OPZERLAG BRISTOL-MYERS SQUIBB COMPANY (A DELAWARE CORPORATION)
1872452 12 Dec 2017 | on 28 Feb 2020 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents. | | 
